Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02797262 · ClinicalTrials.gov registry record · NA

Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System

A NA study, sponsored by University of California, Los Angeles.

Completed
Registry status
NA
Development phase
130
Enrollment target

NCT02797262 is a NA study that has completed, run by University of California, Los Angeles. The registered enrollment target is 130 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02797262, a NA study, has completed, sponsored by University of California, Los Angeles.

COMPLETED
Registry status
NA
Development phase
130 participants
Enrollment target

Study Summary

Introduction of antiretroviral therapy (ART) has transformed HIV-infection from a fatal to manageable disease but adherence to ART remains critical to optimize outcomes. Existing measures of ART adherence provide only inferred measures of actual drug intake and most offer no real-time notification capability. Directly observed therapy measures actual drug intake but is not practical. These limitations constrain research into medication adherence and more importantly, limit our ability to develop real-time interventions based on feasible, in vivo monitoring of adherence among HIV-infected people to facilitate medication-taking. The Proteus digital health feedback (PDHF) system, a pill ingestible sensor based adherence measuring and monitoring system developed by Proteus Digital Health, addresses these limitations. It involves use of an ingestible sensor, a tiny edible material that is over-encapsulated along with prescribed medication. The sensor is activated by ingestion and is sensed by a patch worn by the patient with an embedded monitor and sensor. The monitor sends a Bluetooth signal to a mobile device, which in turn sends an encrypted message to a central server, thus effecting real-time monitoring that a dose has been taken. The investigators propose to develop a data receiving hub and add to these components an automated text message that is sent to the patient when a dose is missed. The investigators will evaluate the feasibility, acceptability and sustainability of using the PDHF system; assess the accuracy of the PDHF system in measuring adherence to ART; and evaluate the efficacy of the PDHF system for monitoring and leveraging adherence to ART.

Interventions

  • DEVICE Proteus digital health feedback (PDHF) system

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2015-09
Est. Completion 2020-10-15
Phase NA

What the Registry Record Tells You About NCT02797262

The ClinicalTrials.gov registry entry for NCT02797262 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Proteus digital health feedback (PDHF) system is the first listed.

NCT02797262 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02797262 about?

NCT02797262 is a clinical study titled "Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System". Introduction of antiretroviral therapy (ART) has transformed HIV-infection from a fatal to manageable disease but adherence to ART remains critical to optimize outcomes. Existing measures of ART adherence provide only inferred measures of actual drug intake and most offer no real-time notification c...

What is the current status of trial NCT02797262?

This trial is currently completed. It is a NA study. The enrollment target is 130 participants. The study started on 2015-09. Estimated completion is 2020-10-15.

What interventions are being tested in trial NCT02797262?

The interventions under investigation include: Proteus digital health feedback (PDHF) system (DEVICE).

Who is sponsoring clinical trial NCT02797262?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.